VA Portland Health Care Services
Welcome,         Profile    Billing    Logout  
 6 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Graff, Julie
NCT04116775: Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Recruiting
2
32
US
Fecal microbiota transplant, FMT, Fecal transplant, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Enzalutamide, Xtandi, MDV3100, ASP9785
Julie Graff, MD, Merck Sharp & Dohme LLC, Prostate Cancer Foundation, Johns Hopkins University, Oregon Health and Science University
Prostate Cancer, Prostate Cancer Metastatic
10/23
10/23
NCT04267887: Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Active, not recruiting
2
7
US
Abiraterone Acetate, CB7630, Yonsa, Zytiga, Antiandrogen Therapy, ADT, Androgen Deprivation Therapy, Androgen Deprivation Therapy (ADT), Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy, Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, Bone Scan, Bone Scintigraphy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Questionnaire Administration
OHSU Knight Cancer Institute, Janssen Scientific Affairs, LLC, Oregon Health and Science University
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
01/28
01/30
NCT02312557: Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Active, not recruiting
2
58
US
Enzalutamide, ASP9785, MDV3100, Xtandi, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
OHSU Knight Cancer Institute, Merck Sharp & Dohme LLC, Collins Medical Trust, Oregon Health and Science University
Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Cancer AJCC v8
06/24
06/24
BRACeD, NCT04038502: Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Recruiting
2
100
US
Carboplatin, Paraplatin, Olaparib, Lynparza
VA Office of Research and Development
Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
08/25
08/25
CaRPET, NCT06610825: Castrate Resistant Prostate Cancer Enhertu Therapy

Not yet recruiting
2
60
NA
Enhertu
Washington D.C. Veterans Affairs Medical Center, Daiichi Sankyo, Cancer Research And Biostatistics, Institute for Clinical Research
Prostate Cancer Metastatic, Prostate Cancer, CRPC
10/27
10/28
VA-BAT, NCT05011383: High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

Recruiting
2
51
US
High dose testosterone, Bipolar androgen therapy
VA Office of Research and Development
Metastatic Prostate Cancer
08/26
08/27
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Active, not recruiting
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
02/25
c15-148, NCT02522715: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Active, not recruiting
1/2
37
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Enzalutamide, ASP9785, MDV3100, Xtandi, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
OHSU Knight Cancer Institute, Oregon Health and Science University
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
10/19
01/25
NCT04706663: Precision-Based Genomics in Prostate Cancer

Recruiting
N/A
2000
US
National Cancer Institute (NCI)
Prostate Cancer
06/26
06/27
Sitch, Miranda
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Active, not recruiting
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
02/25

Download Options